Wavodyne Therapeutics is developing the first generation of drugs to treat neuroinflammation and reduce the memory and cognitive disorders caused by neuroinflammatory processes. The treatment of cognitive disorders associated with HAND and Parkinson’s disease are included in Wavodyne’s product plans. Wavodyne Therapeutics has exclusive patent rights to novel drug candidates which have high selectivity for inhibition of the Mixed Lineage Kinases. Based on standard drug development timelines, regulatory requirements, and the timely completion of our pivotal clinical trials, WavoDyne expects to launch its first product for the treatment in the 2021-2022 time frame.
Visit the Wavodyne Therapeutics website for more information.